About this trial
This study looks at how well tinengotinib works when combined with standard treatments for prostate cancer. The goal is to determine if this combination is safe and causes few side effects. It focuses on men with metastatic castration-resistant prostate cancer, which means the cancer has spread and does not respond to hormonal therapy.
The trial's ID number is NCT06457919. This is a Phase 1b/2 trial, which means it is exploring how well the treatment works and its safety. The study is FDA-regulated and aims to include about 50 participants.
Who can join
Men aged 18 and older can join this study. Participants must have a confirmed diagnosis of prostate cancer that has spread. They should be currently taking standard treatments like abiraterone acetate or enzalutamide. The study team will check to confirm if a person is suitable to join.
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study will take tinengotinib daily for 28-day cycles. Some participants will receive tinengotinib along with abiraterone acetate and prednisone, while others will receive it with enzalutamide. Participants will not be randomly assigned to groups; they will follow a set order for treatments.
Where
This trial is running at 12 locations in the United States. 11 of them are currently recruiting.
Columbia University
New York, New York
Duke University
Durham, North Carolina
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey
Memorial Sloan Kettering Cancer Center
New York, New York
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York
The first 8 of 12 sites are listed here. The registry record has the full list.